Literature DB >> 18948597

Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines.

Dorre A Grueneberg1, Wenliang Li, Joan E Davies, Jacqueline Sawyer, Joseph Pearlberg, Ed Harlow.   

Abstract

Functional differences among human cells have been difficult to identify by standard biochemical methods. Loss-of-function shRNA screens provide an unbiased method to compare protein requirements across cell lines. In previous work, we have studied kinase requirements in two settings, either among a panel of cells from numerous tissues or between two cell lines that differ only by the expression of a chosen oncoprotein or tumor suppressor protein. Here we examine the patterns of kinase requirements between two unrelated cells, the cervical carcinoma cell line HeLa and the renal carcinoma cell line 786-O. By using time courses of cell proliferation after shRNA transduction and by introducing different levels of the shRNAs, we were able to carefully compare the kinase requirements. These comparisons identified 10 kinases that were required in HeLa but not 786-O, and 5 kinases that were required in 786-O but not HeLa. The patterns of growth inhibition due to particular sets of shRNAs in a tumor cell line were shown to be similar in some but not all cell lines derived from the same tissue-specific cancer type. Differential kinase requirements promise to be useful in distinguishing important cell-to-cell functional variations and may lead to the identification of fingerprints for different physiological cell states.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948597      PMCID: PMC2575447          DOI: 10.1073/pnas.0806578105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells.

Authors:  Amy Baldwin; Wenliang Li; Miranda Grace; Joseph Pearlberg; Ed Harlow; Karl Münger; Dorre A Grueneberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

2.  Assessment of the Alamar Blue assay for cellular growth and viability in vitro.

Authors:  G R Nakayama; M C Caton; M P Nova; Z Parandoosh
Journal:  J Immunol Methods       Date:  1997-05-26       Impact factor: 2.303

3.  Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.

Authors:  J O'Brien; I Wilson; T Orton; F Pognan
Journal:  Eur J Biochem       Date:  2000-09

4.  Lentivirus-delivered stable gene silencing by RNAi in primary cells.

Authors:  Sheila A Stewart; Derek M Dykxhoorn; Deborah Palliser; Hana Mizuno; Evan Y Yu; Dong Sung An; David M Sabatini; Irvin S Y Chen; William C Hahn; Phillip A Sharp; Robert A Weinberg; Carl D Novina
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

5.  An approach to genomewide screens of expressed small interfering RNAs in mammalian cells.

Authors:  Lianxing Zheng; Jun Liu; Sergei Batalov; Demin Zhou; Anthony Orth; Sheng Ding; Peter G Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

6.  Tumour suppression by the human von Hippel-Lindau gene product.

Authors:  O Iliopoulos; A Kibel; S Gray; W G Kaelin
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

7.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

8.  A resource for large-scale RNA-interference-based screens in mammals.

Authors:  Patrick J Paddison; Jose M Silva; Douglas S Conklin; Mike Schlabach; Mamie Li; Shola Aruleba; Vivekanand Balija; Andy O'Shaughnessy; Lidia Gnoj; Kim Scobie; Kenneth Chang; Thomas Westbrook; Michele Cleary; Ravi Sachidanandam; W Richard McCombie; Stephen J Elledge; Gregory J Hannon
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

9.  A large-scale RNAi screen in human cells identifies new components of the p53 pathway.

Authors:  Katrien Berns; E Marielle Hijmans; Jasper Mullenders; Thijn R Brummelkamp; Arno Velds; Mike Heimerikx; Ron M Kerkhoven; Mandy Madiredjo; Wouter Nijkamp; Britta Weigelt; Reuven Agami; Wei Ge; Guy Cavet; Peter S Linsley; Roderick L Beijersbergen; René Bernards
Journal:  Nature       Date:  2004-03-25       Impact factor: 49.962

10.  Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells.

Authors:  K Seedorf; T Oltersdorf; G Krämmer; W Röwekamp
Journal:  EMBO J       Date:  1987-01       Impact factor: 11.598

View more
  18 in total

1.  Expression and purification of Src-family kinases for solution NMR studies.

Authors:  Andrea Piserchio; David Cowburn; Ranajeet Ghose
Journal:  Methods Mol Biol       Date:  2012

2.  Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link IFN-γ and p53 signaling.

Authors:  Mathew Sajish; Quansheng Zhou; Shuji Kishi; Delgado M Valdez; Mili Kapoor; Min Guo; Sunhee Lee; Sunghoon Kim; Xiang-Lei Yang; Paul Schimmel
Journal:  Nat Chem Biol       Date:  2012-04-15       Impact factor: 15.040

3.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.

Authors:  Amy Baldwin; Dorre A Grueneberg; Karin Hellner; Jacqueline Sawyer; Miranda Grace; Wenliang Li; Ed Harlow; Karl Munger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

4.  The (un)targeted cancer kinome.

Authors:  Oleg Fedorov; Susanne Müller; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

5.  Rational creation and systematic analysis of cervical cancer kinase-inhibitor binding profile.

Authors:  Min Han; Dongdong Sun
Journal:  J Comput Aided Mol Des       Date:  2019-06-15       Impact factor: 3.686

6.  Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression.

Authors:  Matthew D Christensen; Jacob J Elmer; Seron Eaton; Laura Gonzalez-Malerva; Joshua LaBaer; Kaushal Rege
Journal:  J Control Release       Date:  2015-02-11       Impact factor: 9.776

Review 7.  Protein kinase signaling networks in cancer.

Authors:  John Brognard; Tony Hunter
Journal:  Curr Opin Genet Dev       Date:  2010-11-29       Impact factor: 5.578

8.  GRK3 is essential for metastatic cells and promotes prostate tumor progression.

Authors:  Wenliang Li; Nanping Ai; Suming Wang; Nandita Bhattacharya; Vladimir Vrbanac; Michael Collins; Sabina Signoretti; Yanhui Hu; Frederick M Boyce; Karsten Gravdal; Ole J Halvorsen; Hawa Nalwoga; Lars A Akslen; Ed Harlow; Randolph S Watnick
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

9.  RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma.

Authors:  Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David O Azorsa
Journal:  Mol Cancer       Date:  2010-08-18       Impact factor: 27.401

10.  In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.

Authors:  Corbin E Meacham; Emily E Ho; Esther Dubrovsky; Frank B Gertler; Michael T Hemann
Journal:  Nat Genet       Date:  2009-09-27       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.